Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02952820 · ClinicalTrials.gov registry record · Phase 3
Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 971
- Enrollment target
NCT02952820: Completed Phase 3 study, sponsored by Eisai.
NCT02952820 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 971 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (26% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02952820, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 971 participants
- Enrollment target
Study Summary
The key objectives of this study are to determine, using sleep diaries, whether lemborexant at the doses 5 milligrams (mg) and 10 mg is superior to placebo on subjective sleep onset, subjective sleep efficiency, and subjective sleep maintenance in participants with insomnia disorder.
Primary Outcome
sSOL was defined as estimated minutes from the time that the participant attempted to sleep until sleep onset.
Interventions
- DRUG Placebo
- DRUG lemborexant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 971 participants |
| Start Date | 2016-11-15 |
| Est. Completion | 2019-01-08 |
| Phase | Phase 3 |
What the finished NCT02952820 record still lists
NCT02952820 is an interventional study that assigns participants to a tested intervention. The registered 971 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (26% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02952820 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02952820 about?
NCT02952820 is a clinical study titled "Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)". The key objectives of this study are to determine, using sleep diaries, whether lemborexant at the doses 5 milligrams (mg) and 10 mg is superior to placebo on subjective sleep onset, subjective sleep efficiency, and subjective sleep maintenance in participants with insomnia disorder.
What is the current status of trial NCT02952820?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 971 participants. The study started on 2016-11-15. Estimated completion is 2019-01-08.
What interventions are being tested in trial NCT02952820?
The interventions under investigation include: Placebo (DRUG), lemborexant (DRUG).
Who is sponsoring clinical trial NCT02952820?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02952820's enrollment target sits among peer trials
971 329th of 2000 higher than 1,672 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05354141 · 970 participants · Phase 3
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
- NCT06948422 · 974 participants · Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI